Abstract:
Objective To investigate the predictive value of combined monitoring of infliximab (IFX) trough concentration, anti-infliximab antibody (ATI) levels, and fecal calprotectin (FC) for the disease activity of Crohn’s disease (CD).
Methods A total of 80 CD patients admitted to The Second Affiliated Hospital of Zhejiang Chinese Medical University from January 2022 to December 2024 were enrolled. According to the Crohn’s disease activity index (CDAI) scores, the patients were divided into a remission group (
n = 57) and an active group (
n = 23). Clinical data, IFX trough concentration, ATI levels, and FC were compared between the two groups. Pearson correlation analysis was used to explore the correlations of IFX trough concentration, ATI levels, and FC with CDAI scores. Binary Logistic regression analysis was performed to identify independent influencing factors for disease activity in CD patients. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the predictive value of individual and combined monitoring of each indicator for CD activity.
Results The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in the active group were significantly higher than those in the remission group (all
P < 0.05). IFX trough concentration in the active group was significantly lower than that in the remission group, while the ATI levels and FC were significantly higher (all
P < 0.05). Pearson correlation analysis showed that IFX trough concentration was negatively correlated with CDAI scores (
P < 0.05), and both ATI levels and FC were positively correlated with CDAI scores (all
P < 0.05). Binary Logistic regression analysis indicated that IFX trough concentration, ATI levels, and FC were independent influencing factors for disease activity in CD patients (all
P < 0.05). ROC curve analysis revealed that the areas under the curve (AUC) for predicting CD activity by individual monitoring of IFX trough concentration, ATI levels, FC, and their combined monitoring were 0.784, 0.791, 0.808, and 0.976, respectively.
Conclusion IFX trough concentration, ATI levels, and FC are closely associated with disease activity in CD patients. Combined monitoring of these three parameters can significantly improve the predictive efficacy for CD activity.